What's Happening?
The FDA has approved Partner Therapeutics' drug Bizengri for treating cholangiocarcinoma patients with a specific genetic mutation. This approval follows the recent awarding of a national priority voucher to the drug, which is part of the FDA's Commissioner’s
National Priority Voucher (CNPV) program. Bizengri, a HER2- and HER3-directed bispecific antibody, was previously approved for non-small cell lung cancer and adenocarcinoma with NRG1 gene fusion. The latest approval allows its use in adults with cholangiocarcinoma positive for the NRG1 gene fusion, a rare and aggressive form of cancer. The decision was based on a study showing a 36.8% overall response rate among 19 patients. The CNPV program aims to accelerate drug approvals for rare diseases with unmet needs, although it has faced criticism for lack of transparency.
Why It's Important?
The approval of Bizengri underlines the FDA's commitment to fast-tracking treatments for rare diseases, potentially offering new hope to patients with limited options. The CNPV program, by reducing review times, can significantly impact the availability of critical therapies. However, the program's lack of transparency has raised concerns among stakeholders, including lawmakers, about the criteria for awarding vouchers. This approval could influence future regulatory strategies and encourage pharmaceutical companies to invest in treatments for rare conditions, knowing that expedited pathways are available.
What's Next?
The FDA's CNPV program is likely to continue evolving as it addresses transparency issues. Companies may push for clearer guidelines to understand eligibility for priority vouchers. The success of Bizengri could prompt other pharmaceutical firms to pursue similar pathways for their drugs. Additionally, ongoing discussions in Congress about the program's transparency might lead to legislative changes to ensure more standardized criteria for voucher awards.
